Basilea Pharmaceutica AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David Veitch
- Full Time Employees
- 189
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Hegenheimermattweg 167b Allschwil BL Switzerland 4123
- IPO Date
- Jun 9, 2015
- Website
- basilea.com
- Similar Companies
- Business
- Basilea Pharmaceutica AG (SIX: BSLN), a commercial-stage Swiss biopharmaceutical company founded in 2000 as a spin-off from Roche and headquartered in Allschwil near Basel, Switzerland, discovers, develops and commercializes innovative anti-infective drugs targeting severe bacterial and fungal infections in hospitalized patients; its marketed products comprise the intravenous and oral antifungal Cresemba (isavuconazole), approved in over 70 countries including the US, EU, China and Japan for invasive aspergillosis and mucormycosis with pediatric indications in the US and EU, and the intravenous antibiotic Zevtera (ceftobiprole medocaril), approved in over 80 countries including a 2024 US FDA expansion for Staphylococcus aureus bacteremia including right-sided infective endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia alongside existing pneumonia indications, with US commercial launch in May 2025 via partner Innoviva Specialty Therapeutics. The company advances a pipeline of clinical and preclinical candidates including the novel mechanism antifungals fosmanogepix, acquired from Pfizer in November 2023 and advanced to phase 3 studies in candidemia/invasive candidiasis (initiated September 2024) and invasive mold infections (July 2025) under a September 2024 BARDA agreement providing initial funding and up to USD 268 million potentially, and BAL2062 (acquired October 2023) for invasive mold infections with phase 1 safety demonstrated and QIDP/Orphan/Fast Track US FDA designations; the oral beta-lactam/beta-lactamase inhibitor combination ceftibuten-ledaborbactam etzadroxil, acquired globally in August 2025 with QIDP/Fast Track status for complicated urinary tract infections and phase 3 planned in 18 months under a September 2025 BARDA contract; and the preclinical LptA inhibitor antibiotic BAL2420, acquired from Spexis AG in early 2024 with CARB-X funding including an additional USD 7.3 million award in December 2024 to reach first-in-human trials mid-2026. Basilea generates revenue through royalties, sales milestones and transfer prices from over 100 license and distribution partners worldwide such as Astellas (US for Cresemba), Pfizer (Europe, China, Asia-Pacific for Cresemba), Advanz (Europe for Zevtera excluding Nordics), Hikma (MENA), Knight (Latin America), Asahi Kasei Pharma (Japan), CR Gosun (China) and Avir (Canada); recent milestones include USD 30 million from Pfizer in November 2025 for strong European Cresemba sales, USD 25 million BARDA funding in September 2025 for fosmanogepix/BAL2062 advancement, USD 39 million BARDA tranche in July 2025, USD 25 million from Pfizer in September 2024 for European sales, and pediatric EU approval/extension triggering CHF 10 million in August 2024, with subsidiaries in the UK and Germany supporting operations across North America, Europe, Asia-Pacific, Latin America and MENA amid a strategic focus on anti-infectives since exiting oncology in early 2022.
Company News
Basilea Pharmaceutica AG (BPMUF) Q2 2026 Earnings Call Transcript
Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Basilea provides portfolio update and outlook
Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Basilea Pharmaceutica AG (BPMUF) Q2 2025 Earnings Conference Call Transcript
Basilea on track with strong 2025 half-year results
Assessment of the 14-Alpha Demethylase Inhibitors Pipeline Landscape 2025, Featuring Insights Into Oteseconazole (Mycovia Pharmaceuticals) and Isavuconazonium (Basilea Pharmaceutica)